Most conversations about peptides for fertility center on growth hormone secretagogues or GLP-1s. But there is a peptide that sits at the very top of the reproductive cascade, acting as the master switch for ovulation itself. It is called kisspeptin, and its potential for women with PMOS is among the most genuinely exciting developments in reproductive endocrinology.
What Is Kisspeptin and Why Does It Matter
Kisspeptin is a neuropeptide encoded by the KISS1 gene. It is produced by specialized neurons in the hypothalamus that serve as the primary regulators of the reproductive axis. Kisspeptin neurons are, in practical terms, the on-off switch for GnRH (gonadotropin-releasing hormone) neurons. And GnRH is the signal that tells the pituitary gland to release LH and FSH, which are the hormones that drive ovulation.
This was discovered relatively recently. The critical role of kisspeptin was not understood until the early 2000s, when loss-of-function mutations in the kisspeptin receptor (KISS1R) were found to cause hypogonadotropic hypogonadism, the absence of puberty and reproductive function. Since then, research has established kisspeptin as essential for puberty onset, menstrual cyclicity, and the LH surge that triggers ovulation.
How Kisspeptin Triggers Ovulation
In a normal menstrual cycle, the mid-cycle LH surge is what causes a mature follicle to release an egg. This surge does not happen spontaneously. It requires a precisely timed burst of GnRH from the hypothalamus, which in turn requires activation by kisspeptin neurons.
When researchers at Imperial College London administered kisspeptin-54 (the native 54-amino-acid form) to healthy women, they observed a dose-dependent increase in LH, FSH, and estradiol. More importantly, they demonstrated that kisspeptin-54 could be used to trigger egg maturation in women undergoing IVF, with a crucial safety advantage: it produced virtually no cases of ovarian hyperstimulation syndrome (OHSS).
OHSS is the most dangerous complication of fertility treatment. It can cause fluid retention, kidney problems, blood clots, and in rare cases death. Current standard triggers like hCG carry meaningful OHSS risk. Kisspeptin, because it works through the natural GnRH pathway rather than directly stimulating the ovary, produces a more physiological response with dramatically lower OHSS risk.
The PMOS Connection
PMOS is characterized by anovulation. The ovaries contain multiple small follicles that start to develop but fail to reach the point of ovulation. One of the core reasons is the disordered GnRH pulse pattern that produces the elevated LH:FSH ratio characteristic of the condition.
Kisspeptin sits upstream of this entire cascade. If the GnRH pulse generator is misfiring, kisspeptin is the signal that sets its rhythm. This makes it a uniquely targeted potential intervention for PMOS-related anovulation because it addresses the neuroendocrine root rather than forcing ovulation through pharmacological override.
What the Clinical Trials Show
Clinical studies of kisspeptin in women with PMOS are still in early stages, but the results are promising. Research published in Human Reproduction demonstrated that kisspeptin-54 administered subcutaneously twice daily to women with PCOS induced LH responses at all dose levels tested. In a subset of women, kisspeptin treatment rescued ovulation, though the response was not uniform across all participants.
This is consistent with the heterogeneous nature of PMOS. Women whose anovulation is primarily driven by neuroendocrine dysregulation appear to respond better to kisspeptin than those whose anovulation is driven primarily by severe metabolic dysfunction. This suggests that kisspeptin may be most effective when combined with metabolic interventions like GLP-1 therapy.
A 2026 study published in Frontiers in Endocrinology tracked kisspeptin levels throughout controlled ovarian stimulation in PMOS patients and found that kisspeptin dynamics correlated with follicular development quality and pregnancy outcomes, supporting its role as both a biomarker and potential therapeutic target.
Kisspeptin vs Clomiphene vs Letrozole
Current first-line ovulation induction treatments for PMOS are clomiphene citrate and letrozole. Both are effective but have limitations. Clomiphene works by blocking estrogen receptors in the hypothalamus, tricking the brain into releasing more FSH. Letrozole works by temporarily reducing estrogen production, achieving a similar effect. Both can cause multiple ovulations (increasing twin risk) and neither addresses the underlying neuroendocrine disruption.
Kisspeptin represents a fundamentally different approach. It does not trick or override the system. It communicates through the natural regulatory pathway. In IVF studies, kisspeptin-triggered cycles produced oocytes of comparable quality to hCG-triggered cycles with dramatically reduced OHSS risk. For non-IVF ovulation induction in PMOS, the potential to restore physiological cycling rather than forcing pharmacological ovulation is the primary appeal.
MVT-602: The Next-Generation Kisspeptin Agonist
Native kisspeptin-54 has a short half-life, requiring frequent injections. MVT-602 is a kisspeptin receptor agonist developed to address this limitation. In a study published in the Journal of Clinical Investigation, MVT-602 produced a markedly prolonged pharmacodynamic effect compared to native kisspeptin-54, with peak LH occurring at 21 to 22 hours versus 4.7 hours.
Importantly, the study directly compared MVT-602 in healthy women, women with PCOS, and women with hypothalamic amenorrhea. The results showed that both MVT-602 and kisspeptin-54 induced similar peak LH amplitudes across all three groups, confirming that the kisspeptin pathway remains functionally responsive in women with PMOS, even though it is dysregulated.
The Surprising Insulin Resistance Connection
Kisspeptin's relevance to PMOS extends beyond ovulation. A 2026 study published in PLOS ONE demonstrated that kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. This finding suggests that kisspeptin addresses two of the four root dysfunctions of PMOS simultaneously: the neuroendocrine disruption and the ovarian insulin resistance.
Kisspeptin is not just a fertility peptide. It is a regulator of the entire neuroendocrine system that is disrupted in PMOS. Future PMOS therapy may involve kisspeptin for neuroendocrine normalization combined with GLP-1 RAs for systemic metabolic improvement, addressing the condition from both ends of the cascade.
Where This Is Going
Kisspeptin is still in the research and clinical trial phase for PMOS specifically. It is not yet FDA-approved for any indication. But the trajectory is clear: kisspeptin-based therapies are being developed as both IVF triggers (where they may largely replace hCG) and as potential treatments for anovulatory infertility.
For women with PMOS, kisspeptin represents something rare in the treatment landscape: a therapy that works with the body's natural regulatory system rather than against it. It does not override the axis. It resets it.